Tarsons Products Limited has informed the Exchange regarding Change in Director(s) of the company.
TARSONS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tarsons Products has announced multiple changes to its board effective 4th August 2025. Dr. Monjori Mitra, a pediatrician with about 24 years of experience in infectious disease and vaccinology, has been appointed as a Non-Executive Independent Director for a 5-year term, subject to shareholder approval. Mr. Ramanathan Subramanian Arun Kumar, a finance professional with nearly 30 years of experience (including senior roles at PineBridge Investments, JP Morgan, and Bahrain's Sovereign Wealth Fund), has been appointed as Non-Executive Nominee Director representing private equity investor Clear Vision Investment Holdings. Meanwhile, Mr. Suresh Eshwara Prabhala stepped down as Clear Vision's nominee director due to personal reasons but was simultaneously reappointed to the board as a Non-Executive Non-Independent Director, so he continues on the board in a different capacity.
This is a routine board reshuffle driven by the private equity investor (Clear Vision) replacing its nominee representative. The addition of a medical expert as Independent Director strengthens governance and domain expertise. The stock price is unlikely to be materially impacted as the outgoing director remains on the board and the changes are largely procedural.